Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.55 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | CSF1R | P07333 | 3/20 | 0.52 |
| ▸ | LYN | P07948 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | FLT4 | P35916 | 3/20 | 0.52 |
| ▸ | BLK | P51451 | 3/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | MET | P08581 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | FRK | P42685 | 2/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842668 | 0.90 | KDR (0.59) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL13873225 | 0.90 | CSF1R (0.53) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL4216606 | 0.88 | FLT1 (0.56) | FLT1NTRK1LCKCSF1RLYN | |
| SCHEMBL3851409 | 0.87 | RAF1 (0.54) | FLT1NTRK1LCKCSF1RLYN | |
| SCHEMBL3851039 | 0.87 | NTRK1 (0.51) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL3845211 | 0.87 | KDR (0.58) | FLT1NTRK1LCKCSF1RLYN | |
| SCHEMBL13873367 | 0.86 | LCK (0.50) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL3847163 | 0.86 | BRAF (0.57) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL13873087 | 0.85 | MAP4K4 (0.49) | RIPK1FLT1NTRK1LCKCSF1R | |
| SCHEMBL3845205 | 0.85 | SRPK1 (0.49) | FLT1NTRK1LCKCSF1RLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125808-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-02 | — | — | EP | claimed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | claimed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | claimed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | RIPK1 2838/4885FLT1 4/4885NTRK1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.